Edward Kaye - Cytokinetics Director

CYTK
 Stock
  

USD 47.77  0.47  0.99%   

  Director
Dr. Edward M. Kaye is Independent Director of the Company. Dr. Kaye has served as the Chief Executive Officer of Stoke Therapeutics since 2017. Previously, he served as the Chief Executive Officer of Sarepta, as well as the Chief Medical Officer, from 2011 to 2017. Prior to joining Sarepta, Dr. Kaye was employed by Genzyme Corporationrationration for ten years, holding various senior management positions, the most recent of which was Group Vice President of Clinical Development, in which he supervised clinical research in lysosomal storage disease programs and genetic neurological disorders. Previously, Dr. Kaye served as Chief of Biochemical Genetics at Childrens Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics at the University of Pennsylvania School of Medicine. Dr. Kaye serves as a Neurological Consultant at the Childrens Hospital of Boston and is on the editorial boards of a number of medical journals. He is also a member of several scientific advisory boards, including United Leukodystrophy Foundation, Spinal Muscular Atrophy Foundation, CureCMD, CureDuchenne and Prize4Life. Dr. Kaye received his medical education and pediatric training at Loyola University Stritch School of Medicine and University Hospital, child neurology training at Boston City Hospital, Boston University, and completed his training as a neurochemical research fellow at Bedford VA Hospital, Boston University.
Age: 69  Director Since 2016      
650 624-3000  www.cytokinetics.com
Kaye earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine. He received his Pediatric training at Loyola University Hospital, Child Neurology training at Boston City Hospital, Boston University, and completed his training as a Neurochemical Research Fellow at Bedford VA Hospital, Boston University.

Cytokinetics Management Efficiency

Cytokinetics has return on total asset (ROA) of (16.94) % which means that it has lost $16.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (120.54) %, meaning that it created substantial loss on money invested by shareholders. Cytokinetics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -63.24. The current Return on Average Assets is estimated to decrease to -0.33. The current Total Liabilities is estimated to increase to about 644.6 M. The current Current Liabilities is estimated to increase to about 77.5 M
The company currently holds 269.93 M in liabilities with Debt to Equity (D/E) ratio of 1.11, which is about average as compared to similar companies. Cytokinetics has a current ratio of 7.3, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Cytokinetics until it has trouble settling it off, either with new capital or with free cash flow. So, Cytokinetics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cytokinetics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cytokinetics to invest in growth at high rates of return. When we think about Cytokinetics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Rochelle LazarusGeneral Electric
2000
Risa LavizzoMoureyGeneral Electric
2017
Paula ReynoldsGeneral Electric
2018
Marijn DekkersGeneral Electric
2012
Thomas HortonGeneral Electric
2018
Peter HenryGeneral Electric
2016
Leslie SeidmanGeneral Electric
2018
Steven MollenkopfGeneral Electric
2016
James MulvaGeneral Electric
2008
Andrea JungGeneral Electric
1998
Robert LaneGeneral Electric
2005
Edward GardenGeneral Electric
2017
Sebastien BazinGeneral Electric
2016
Robert SwieringaGeneral Electric
N/A
Mary SchapiroGeneral Electric
2013
William BeattieGeneral Electric
2009
James RohrGeneral Electric
2013
Susan HockfieldGeneral Electric
2006
James TischGeneral Electric
2010
Lowell McAdamGeneral Electric
2016
John BrennanGeneral Electric
2014
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people. Cytokinetics (CYTK) is traded on NASDAQ Exchange in USA. It is located in 350 Oyster Point Boulevard, South San Francisco, CA 94080, United States and employs 253 people. Cytokinetics is listed under Pharmaceutical Products category by Fama And French industry classification.

Cytokinetics Leadership Team

Elected by the shareholders, the Cytokinetics' board of directors comprises two types of representatives: Cytokinetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytokinetics. The board's role is to monitor Cytokinetics' management team and ensure that shareholders' interests are well served. Cytokinetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytokinetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Edward Kaye, Director
Bradley Morgan, Senior Vice President - Drug Discovery and Early Development
Leonard Gage, Independent Chairman of the Board
Caryn McDowell, Chief Compliance Officer, Vice President General Counsel
Robert Wong, Chief Accounting Officer, Vice President
John Henderson, Independent Director
Sharon Barbari, CFO, Executive Vice President - Finance
Peter Roddy, Senior Vice President Chief Accounting Officer
Mark Schlossberg, Senior Vice President Legal and General Counsel
David Cragg, Sr. VP of HR
Elisabeth Schnieders, Senior Vice President - Business Development
Joanna Goldstein, IR Contact Officer
Wendall Wierenga, Independent Director
Santo Costa, Independent Director
Robert Califf, Director
Fady Malik, Senior Vice President - Research and Early Development
Wendell Wierenga, Independent Director
Lynne Parshall, Independent Director
Ching Jaw, CFO, Senior Vice President
Bonnie Charpentier, Sr. VP of Regulatory Affairs and Compliance
Robert Blum, CEO and President Director and Chief Executive of the Biopharmaceutical Concern
Sandford Smith, Independent Director
Andrew Wolff, Senior Vice President - Clinical Research and Development, Chief Medical Officer
Diane Weiser, IR Contact Officer

Cytokinetics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cytokinetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.2 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.